Metabolic Effects of Exogenous 3-hydroxybutyrate in Patients With Type 1 Diabetes and Healthy Controls
Metabolic Effects of Exogenous 3-hydroxybutyrate in Patients With Type 1 Diabetes and Healthy Controls
The main objective of this clinical trial is to study the metabolic effects of intravenous
 infusion of the ketone body, 3-hydroxybutyrate (3-OHB), in patients with type 1 diabetes and
 healthy control subjects. Moreover, the investigators plan to examine regulatory mechanisms
 of 3-OHB that may be related to diabetic ketoacidosis.

 The hypotheses are:

 1. 3-OHB related inhibition of lipolysis is impaired in patients with type 1 diabetes.

 2. Intravenous infusion of 3-OHB affects signaling pathways involved in the metabolic
 regulation in patients with type 1 diabetes and healthy controls.

 3. 3-OHB infusion improves cardiac function in patients with type 1 diabetes and healthy
 controls.

 The effects of 3-OHB will be investigated by isotopic tracers examinations, fat and muscle
 biopsies and blood samples. To evaluate effects on cardiac function echocardiography will be
 performed.
Patients with type 1 diabetes:

 Inclusion Criteria:

 -  Type 1 diabetes diagnosis

 -  C-peptide negative

 -  19 < BMI < 26

 -  written consent

 Exclusion Criteria:

 -  Severe comorbidity

 -  Regular medication apart from insulin (except over-the-counter medicines)

 -  Use of long acting insulin analogues, that work > 24 hours, e.g. Tresiba

 -  PI finds the patient not fit (e.g. mental illness, too nervous, unacceptable screening
 blood tests or other).

 Healthy control subjects:

 Inclusion Criteria:

 -  19 < BMI < 26

 -  written consent

 Exclusion Criteria:

 -  Chronic disease

 -  Regular medication (except over-the-counter medicines)

 -  PI finds the patient not fit (e.g. mental illness, too nervous, unacceptable screening
 blood tests or other).